PMID- 24202700
OWN - NLM
STAT- MEDLINE
DCOM- 20150212
LR  - 20211021
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 38
IP  - 1
DP  - 2014 Jul
TI  - Decreased circulating microRNA-223 level predicts high on-treatment platelet 
      reactivity in patients with troponin-negative non-ST elevation acute coronary 
      syndrome.
PG  - 65-72
LID - 10.1007/s11239-013-1022-9 [doi]
AB  - To investigate the relationship between circulating microRNA 223 (miR-223) levels 
      and clopidogrel responsiveness in patients with coronary heart disease. A total 
      of 62 consecutive patients with troponin-negative non-ST elevation acute coronary 
      syndrome (NSTE-ACS) scheduled for elective percutaneous coronary intervention 
      were enrolled. The plasma circulating miR-223 levels were quantified by real-time 
      PCR, and platelet reactivity was determined by platelet reactivity index (PRI), 
      measured by vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow 
      cytometry after 300 mg (for at least 24 h) or 75 mg clopidogel (for at least 5 
      days) plus aspirin treatment. All subjects were dichotomized according to PRI 
      median (normal-responders: PRI </= 56.3%, n = 31 and low-responders: PRI > 56.3%, n 
      = 31). Compared with normal-responders, circulating miR-223 level was 
      significantly decreased in low-responders (P = 0.007). In addition, miR-223 level 
      was statistically correlated with PRI (Spearman r = -0.379, P = 0.002). Stepwise 
      binary logistic regression analysis revealed that among factors that potentially 
      influence platelet reactivity (CYP2C19*2/*3 loss-of-function genotypes, use of 
      calcium channel blockers/proton-pump inhibitors, age, diabetes and smoking), 
      decreased circulating miR-223 level was the only independent predictor for the 
      presence of PRI-determined lower responders (OR 0.111, 95% CI 0.018-0.692, P = 
      0.019). Our data suggest that circulating miR-223 may serve as a novel biomarker 
      for assessment of clopidogrel responsiveness in troponin-negative NSTE-ACS 
      patients.
FAU - Zhang, Ying-Ying
AU  - Zhang YY
AD  - Graduate School of Medicine, Tianjin Medical University, Tianjin, China.
FAU - Zhou, Xin
AU  - Zhou X
FAU - Ji, Wen-Jie
AU  - Ji WJ
FAU - Shi, Rui
AU  - Shi R
FAU - Lu, Rui-Yi
AU  - Lu RY
FAU - Li, Jin-Long
AU  - Li JL
FAU - Yang, Guo-Hong
AU  - Yang GH
FAU - Luo, Tao
AU  - Luo T
FAU - Zhang, Jian-Qi
AU  - Zhang JQ
FAU - Zhao, Ji-Hong
AU  - Zhao JH
FAU - Jiang, Tie-Min
AU  - Jiang TM
FAU - Li, Yu-Ming
AU  - Li YM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Biomarkers)
RN  - 0 (MIRN223 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Troponin)
RN  - A74586SNO7 (Clopidogrel)
RN  - EC 1.14.14.1 (CYP2C19 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*blood/*drug therapy/genetics
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Biomarkers/blood
MH  - Blood Platelets/*metabolism
MH  - Clopidogrel
MH  - Cytochrome P-450 CYP2C19/blood/genetics
MH  - Female
MH  - Humans
MH  - Male
MH  - MicroRNAs/*blood/genetics
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Real-Time Polymerase Chain Reaction
MH  - Retrospective Studies
MH  - Ticlopidine/administration & dosage/*analogs & derivatives
MH  - Troponin/genetics/metabolism
EDAT- 2013/11/10 06:00
MHDA- 2015/02/13 06:00
CRDT- 2013/11/09 06:00
PHST- 2013/11/09 06:00 [entrez]
PHST- 2013/11/10 06:00 [pubmed]
PHST- 2015/02/13 06:00 [medline]
AID - 10.1007/s11239-013-1022-9 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2014 Jul;38(1):65-72. doi: 10.1007/s11239-013-1022-9.